Transaction

Anara Impact Capital, Global Innovation Fund, and Africa Health Ventures invest USD 1.45 million in Reme-D

Announced
24 July 2026
Target
Reme-D, Inc.
Value
$1.5m
Asset class
Venture Capital
Type
Investment
Instrument
Ordinary Shares (Equity)
Lead investors
Anara Impact Capital
Investors
Anara Impact Capital, Africa Health Ventures, Undisclosed Investors, Global Innovation Fund
Sector
Healthcare / Medical Supplies, Biotechnology
Markets
Egypt, Kenya, Sudan

About the target

Reme-D, Inc. is an Egypt-based molecular-diagnostics manufacturer that develops diagnostic kits for infectious, genetic and other diseases. The company manufactures molecular tests designed for use in settings with limited cold-chain and laboratory infrastructure, including tests for tuberculosis, human immunodeficiency virus, hepatitis and human papillomavirus. Reme-D sells to public and private laboratories, hospitals and research institutions. Its website lists nucleic-acid extraction, diagnostic and research-use tools, while recent funding coverage reports that it has commercialised 30 products and supplied more than 550,000 tests in Egypt, Kenya and Sudan.

Sources

  1. disruptafrica.com
  2. Partner Researchers